Hematologic Malignancy
Lymphoblastic Lymphoma
CI-CAN-00001100LBLExplore in graph →
Hematologic58 active trials
- NCIt
- C9360
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001100LBLExplore in graph →
Clinical trials
263 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (47)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04943952 | JZP458 - Recombinant Erwinia Asparaginase for Treatment of ALL / LBL Patients With Hypersensitivity to E. Coli-derived Asparaginase | approved for marketing | — | — | Jazz PharmaceuticalsINDUSTRY | 0 | Aug 3, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Aug 3, 2021source: clinicaltrials